Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

antibody

Cannabinoid receptor CB1 polyclonal antibody (DY-682 conjugate)

ADI-905-817-100

100 µg

polyclonal

domestic rabbit

nonconjugated

human, mouse, rat, chicken

ADI-905-817-100

Cannabinoid receptor CB1 polyclonal antibody (DY-682 conjugate)

Rabbit

Polyclonal

DY-682

Antibody

100 µg

Human, Mouse, Rat, Chicken

The cannabinoid receptors CB1 and CB2 are members of the seven-transmembrane family of G-protein coupled receptors (GPCRs), and are named for their signaling function in response to cannabinoid drugs such as delta 9- tetrahydrocannabinol (delta 9-THC). CB1 and CB2 differ significantly in the length of their extracellular amino terminal domain, which is longer in CB1 (116 residues) than in CB2 (33 residues). The CB1 receptor is expressed primarily in the brain and neuronal tissue, and is highly conserved, exhibiting 97-98% amino acid sequence identity across human, mouse, and rat species. In contrast, expression of the CB2 receptor is absent in normal nervous tissue, with expression most prominent in immune tissue such as the spleen. In addition to delta 9-THC and its synthetic analogs, CB1 and CB2 receptors are bound by endogenous eicosanoid ligands, and signal via Gi/o proteins to regulate adenylyl cyclase activity (generally inhibitory), ion channel activation, intracellular Ca2+ levels, nitric oxide synthase activation, and immediate early gene expression. CB1 and CB2 signals in turn regulate neurological and immunological functions such as inhibition of neurotransmitter release and immune cell migration, antigen processing, and cytokine production.

CB1, CNR1, CBR

Synthetic peptide corresponding to the sequence near the N-terminus of mouse cannabinoid receptor CB1.

Liquid. In PBS containing 50% glycerol and 0.01% sodium azide.

Predicted MW of ~53kDa. Higher MW species may also be observed by Western blot which reflect post-translational modification of the receptor.

WB

-20°C